Linked Life Data

20111886

Source:http://linkedlifedata.com/resource/pubmed/id/20111886

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2010-5-13
pubmed:abstractText
Although the disease-modifying anti-rheumatic drugs (DMARD) have been widely used in clinics, rheumatoid arthritis (RA) is not completely curable so far. Hence, to seek new drugs for the treatment of RA has become a pursuing goal of rheumatologists and orthopedic surgeons. Since the major pathological characteristic of RA is inflammation, the exploration of anti-inflammatory drugs has become a hotspot. Moreover, the anti-inflammatory and anti-nociceptive functions of nicotinic acetylcholine receptors as well as the related mechanisms have been recently discovered. Based on the above-mentioned, it is promising that the nicotinic acetylcholine receptor agonists will be applied for the treatment of RA. Following in vitro, in vivo experiments as well as clinical trials will even strengthen this viewpoint and more RA patients will benefit from the application of such agents.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1420-908X
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
59
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
415-7
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
The potential application of nicotinic acetylcholine receptor agonists for the treatment of rheumatoid arthritis.
pubmed:affiliation
The Translational Medicine R&D Center, Shenzhen Institute of Advanced Technology, Chinese Academy of Science, Shenzhen, GuangDong Province, China. superzhangpeng@163.com
pubmed:publicationType
Journal Article, Review